Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We previously showed that exenatide (EXE) enhanced insulin secretion after 1 year of treatment, relative to insulin glargine (GLAR), with a similar glucose-lowering action. These effects were not sustained after a 4-week off-drug period. This article reports the results after additional 2 years of exposure. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomized to EXE or GLAR. Forty-six patients entered the 2-year extension study in which they continued their allocated therapy. Thirty-six completed (EXE: n = 16; GLAR: n = 20) the 3-year exposure period. Insulin sensitivity (M value) and β-cell function were measured by euglycemic hyperinsulinemic clamp followed by hyperglycemic clamp with arginine stimulation at pretreatment (week 52) and 4 weeks after discontinuation of study medication (week 56 and week 172). First-phase glucose stimulated C-peptide secretion was adjusted for M value and calculated as the disposition index (DI). RESULTS: At 3 years, EXE and GLAR resulted in similar levels of glycemic control: 6.6 ± 0.2% and 6.9 ± 0.2%, respectively (P = 0.186). EXE compared with GLAR significantly reduced body weight (−7.9 ± 1.8 kg; P < 0.001). After the 4-week off-drug period, EXE increased the M value by 39% (P = 0.006) while GLAR had no effect (P = 0.647). Following the 4-week off-drug period, the DI, compared with pretreatment, increased with EXE, but decreased with GLAR (1.43 ± 0.78 and −0.99 ± 0.65, respectively; P = 0.028). CONCLUSIONS: EXE and GLAR sustained HbA1c over the 3-year treatment period, while EXE reduced body weight and GLAR increased body weight. Following the 3-year treatment with EXE, the DI was sustained after a 4-week off-drug period. These findings suggest a beneficial effect on β-cell health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [73]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The long-term effects of GLP-1RA go beyond the improvement in glucose metabolism and weight loss [34,35,36,37,38,39] and it is now established their beneficial effects of hepatic metabolism and histology.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [35]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Further analyses from TODAY show that in youth with type 2 diabetes dyslipidaemia162 and hypertension163 are common and worsen over time.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [162]
Experimental — accuracy not yet measuredIn the citing paper
“In one study of exenatide,25 patients underwent two treatment phases—52 weeks followed by 104 weeks—with a 12-week off-treatment period after each phase.”
From Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression (2026) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 3×
“EXE predominantly lowers postprandial glucose by a glucose-dependent stimulation of insulin secretion, inhibition of an inappropriate glucagon secretion, and by slowing down gastric emptying (6).”
BackgroundResultInfluentialNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Although human data are not available, exposure to GLP-1 and GLP-1RA in the preclinical setting results in b-cell proliferation, islet neogenesis, and inhibition of b-cell apoptosis in (human) cell lines, primary rodent islets, and in vivo in different rodent species (13).”
BackgroundKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 2×
“The disposition index (DI), a measure of b-cell function and adjusted for insulin sensitivity, was calculated bymultiplying the firstphase incremental C-peptide secretion with the M value (AIRgluc*M) (12).”
BackgroundMethodZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“(21) was the first to report a beneficial effect of continuous GLP-1 infusion on clamp-measured b-cell function as well as insulin sensitivity in the presence of concomitant weight loss of 1.”
BackgroundCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Cited by
Items 101–200 of 241
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
Ando, T., Haraguchi, A., Matsunaga, T., Natsuda, S., Yamasaki, H., Usa, T., & Kawakami, A. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.1646 · Cited by 31
“GLP-1 analogues have recently been used as antidiabetic agents, and the improvement of the beta-cell function in patients with type 2 diabetes mellitus (DM) has been reported after three years of treatment with exenatide, a GLP-1 analogue (11).”
BackgroundBlonde, L., Anderson, J. E., Chava, P., & Dendy, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541790 · Cited by 33
Cardiovascular Protection with Anti-hyperglycemic Agents
DEEDWANIA, P. C., & Acharya, T. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00325-9 · Cited by 33
“Compared to basal insulin, GLP-1 analogs cause weight loss rather than weight gain [24].”
BackgroundVilsbøll, T., & Garber, A. J. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30
“028), suggesting a possible sustained improvement in β-cell health [35].”
BackgroundKim, M., Park, H. K., Byun, D. W., Suh, K. I., & Hur, K. Y. (2013) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2013.09.008 · Cited by 30
Vora, J. P., Bain, S. C., Damcı, T., Dzida, G. J., Hollander, P. A., Meneghini, L., & Ross, S. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.002 · Cited by 34
NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
Welters, A., Kluppel, C. A., Mrugala, J., Wörmeyer, L., Meißner, T., Mayatepek, E., Heiß, C., Eberhard, D., & Lammert, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13017 · Cited by 37
DiNicolantonio, J. J., & McCarty, M. F. (2019) · Open Heart · doi:10.1136/openhrt-2019-001028 · Cited by 30
“Exenatide therapy, as opposed to insulin therapy, has a more favourable impact on beta cell function over 3 years of follow-up.(114) 115 Recent evidence indicates that oral arginine can potentiate meal-evoked GLP-1 secretion in mice and humans; whether citrulline shares this property remains to be determined.”
Cardiovascular outcome trials of the newer anti-diabetic medications
Acharya, T., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.08.003 · Cited by 31
Scheen, A. J. (2011) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.10.007 · Cited by 31
“In a recent study comparing exposure to exenatide 10 μg twice daily to glargine for 3 years in metformin-treated T2DM patients, most of the effect on insulin secretion observed on exenatide treatment seems to have vanished following a 4-week off-drug period [26].”
BackgroundAn Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
Edwards, K. L., Stapleton, M., Weis, J., & Irons, B. K. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0098.edw · Cited by 32
“15,16,33,38,44,48,49 A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS recent meta-analysis was published that reviewed 25 trials in adults with a body mass index of 25 kg/m 2 or greater, with or without T2DM, and receiving exenatide twice-daily, exenatide once weekly, or liraglutide once daily for 20…”
van Raalte, D. H., Bunck, M. C. M., Smits, M. M., Hoekstra, T., Cornér, A., Diamant, M., Eliasson, B., Marja-RiittaTaskinen, Heine, R. J., Smith, U., et al. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0286 · Cited by 31
Self-citationShin, M.-S., Yu, J. H., Jung, C. H., Hwang, J. Y., Lee, W. J., Kim, M., & Park, J. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0144 · Cited by 26
“41,42 However, because exenatide has not been used extensively in our clinics for several years, the duration of exenatide treatment was not analyzed in our current study.”
Thong, K. Y., McDonald, T. J., Hattersley, A. T., Blann, A. D., Ramtoola, S., Duncan, C., Carr, S. V., Adamson, K., Nayak, A., Khurana, R., et al. (2013) · Diabetic Medicine · doi:10.1111/dme.12367 · Cited by 24
Hyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Potential use of exenatide for the treatment of obesity
Folli, F., & Guardado Mendoza, R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.630660 · Cited by 26
Lamont, B. J., & Andrikopoulos, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0577 · Cited by 28
“Given that the majority of clinical trials recruit obese and insulin-resistant patients with type 2 diabetes over the age of 40 years, it is perhaps not surprising that we have not seen any indirect evidence of b-cell regeneration with exenatide (Bunck et al. 2011) or liraglutide (Garber et al.”
BackgroundPancreatic β cell regeneration induced by clinical and preclinical agents
Wang, K., Tao, M., Wei, T., & Wei, R. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i1.64 · Cited by 30
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
What are the pharmacotherapy options for treating prediabetes?
Daniele, G., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.944160 · Cited by 26
“Studies from our group and others have demonstrated that the primary defect in IGT and T2DM is an inability of the b-cell to respond to glucose [26,34], and this b-cell ‘blindness’ to glucose, at least in part, can be restored by incretin hormones [120].”
BackgroundInfluentialSchwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?
Chikara, G., Sharma, P. K., Dwivedi, P., Charan, J., Ambwani, S. R., & Singh, S. (2017) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0668-z · Cited by 29
“GLP-1 analogs restore b-cells glucose sensitivity in T2DM patients [30].”
BackgroundJi, L., Chan, J. C. N., Yu, M., Yoon, K., Kim, S. G., Choi, S. H., Huang, C., Tu, S., Wang, C., Paldánius, P. M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14205 · Cited by 28
Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes
Edwards, K. L., & Minze, M. G. (2015) · Core evidence · doi:10.2147/ce.s55944 · Cited by 24
“Although this was not shown to be detectable in older rodent models or human trials, there is evidence of preservation of β-cell function after 3 years of treatment with short acting exenatide.(29) Studies currently completed with dulaglutide have shown an increase in β-cell”
BackgroundIncretin-Based Therapy and the Quest for Sustained Improvements in β-Cell Health
Drucker, D. J. (2011) · Diabetes Care · doi:10.2337/dc11-0986 · Cited by 25
Gu, S., Wang, X., Qiao, Q., Gao, W., Wang, J., & Dong, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12991 · Cited by 24
Abdul‐Ghani, M., Migahid, O., Megahed, A., DeFronzo, R. A., Al‐Ozairi, E., & Jayyousi, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14153 · Cited by 21
Sadhu, A., Schwartz, S. S., & Herman, M. E. (2015) · Endocrine Practice · doi:10.4158/ep14569.ra · Cited by 23
“Additionally, GLP-1- and DPP-4-targeted therapies have each been found to inhibit pancreatic beta cell apoptosis and stimulate the proliferation and differentiation of insulin-secreting beta cells (34,35).”
Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 24
Current Therapies for the Medical Management of Diabetes
Inzucchi, S. E., & Majumdar, S. K. (2016) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001332 · Cited by 21
Retnakaran, R. R., Ye, C., Emery, A., Kramer, C. K., & Zinman, B. (2022) · Nature Communications · doi:10.1038/s41467-022-33867-9 · Cited by 21
Liu, J., Yang, K., Xiao, W., Le, Y., Lang, S., Zhang, J., Wei, R., Yang, J., & Hong, T. (2018) · Peptides · doi:10.1016/j.peptides.2018.07.001 · Cited by 20
Palmér, R., Nyman, E., Penney, M., Marley, A., Cedersund, G., & Agoram, B. M. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.16 · Cited by 19
“34 The absence of data on therapies known to cause β -cell changes in T2DM patients limits our ability to apply anything but the simplest level of interpretation to model predictions.”
Effects of dietary vitamins on obesity-related metabolic parameters
Lee, C. Y. (2023) · Journal of Nutritional Science · doi:10.1017/jns.2023.30 · Cited by 23
“discontinued((8)), and liraglutide is of no exception.”
Lim, S. K., Ku, E. J., Lee, S. Y., Lee, J. H., Lee, J.-E., Kim, K. M., & Davies, M. J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000807 · Cited by 26
Targeting beta-cell preservation in the management of type 2 diabetes
Boughton, C. K., Munro, N. M., & Whyte, M. (2017) · British Journal of Diabetes · doi:10.15277/bjd.2017.148 · Cited by 24
Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes
Mudaliar, S. R. D. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12154 · Cited by 19
Fujiwara, D., Takahashi, K., Suzuki, T., Shii, M., Nakashima, Y., Takekawa, S., Yoshida, A., & Matsuoka, T. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12103 · Cited by 18
Long-acting glucagon-like peptide-1 receptor agonist—status December 2018
Holst, J. J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.09 · Cited by 21
“In both groups beta cell function was preserved over a period of 3 years (9).”
BackgroundEvolving Treatment Strategies for the Management of Type 2 Diabetes
Cefalu, W. T. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31823ea4af · Cited by 20
Watada, H., Shiramoto, M., Irie, S., Terauchi, Y., Yamada, Y., Shiosakai, K., Myobatake, Y., & Taguchi, T. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12849 · Cited by 16
Tran, S., Kramer, C. K., Zinman, B., Choi, H., & Retnakaran, R. R. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2017 · Cited by 17
Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?
van Raalte, D. H., & Verchere, C. B. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.04.009 · Cited by 19
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus
Ryan, G. J., Moniri, N. H., & Smiley, D. D. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120168 · Cited by 19
Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy
Kumar, A. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.904851 · Cited by 17
Kubo, F., Miyatsuka, T., Sasaki, S., Takahara, M., Yamamoto, Y., Shimo, N., Watada, H., Kaneto, H., GANNON, M. A., Matsuoka, T., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.177 · Cited by 18
Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?
Clapham, J. C. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9882-1_1 · Cited by 19
Ali, A. M., Mari, A., MARTINEZ, R. A., Jobori, H. A., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., Cersósimo, E., & Abdul‐Ghani, M. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa494 · Cited by 16
Deng, H., Lin, S., Yang, X., Lv, J., Luo, S., Zeng, L., Weng, J., Xu, W., & On Behalf of the CONFIDENCE Group (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12883 · Cited by 20
Moon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 15
Type 2 diabetes: remission in just a week
Yki‐Järvinen, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2266-6 · Cited by 14
“Even the most exciting new drugs, such as dipeptidylpeptidase IV inhibitors or glucagon-like peptide 1 agonists, seem to fail to produce persistent improvements in beta cell function [4, 5].”
BackgroundSelf-citationGastaldelli, A., Nauck, M. A., & Balena, R. (2013) · Metabolism · doi:10.1016/j.metabol.2013.05.001 · Cited by 15
“[35] Bunck MC, Corner A, Eliasson B, et al.”
BackgroundMethodEfficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c
Abdul-Ghani, M. A., Migahid, O., Megahed, A., DeFronzo, R. A., Zirie, M. A., & Jayyousi, A. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3423 · Cited by 15
Individuals With Prediabetes Display Different Age-Related Pathophysiological Characteristics
Fiorentino, T. V., Pedace, E., Succurro, E., Andreozzi, F., Perticone, M., Sciacqua, A., Perticone, F., & Sesti, G. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02610 · Cited by 17
Exendin-4 induces a novel extended effect of ischemic tolerance via crosstalk with IGF-1R
Zhang, H., Liu, Y., Cheng, L., Ma, X., & Luo, X. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.11.008 · Cited by 16
Giuseppe, G. D., Ciccarelli, G., CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Capece, U., Pontecorvi, A., Giaccari, A., & Mezza, T. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.21.03405-9 · Cited by 17
Obesity, Type 2 Diabetes and Beta Cell Failure: An Asian Perspective
Saisho, Y. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.s1-008 · Cited by 18
“Incretin therapy has been shown to increase beta cell mass in rodents; however, this effect has not been confirmed in humans [64,65].”
BackgroundPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_8 · Cited by 16
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch25 · Cited by 35
Liu, J., Hu, Y., Xu, Y., Jia, Y., Li, M., & Wang, G. (2017) · International Journal of Endocrinology · doi:10.1155/2017/9401606 · Cited by 13
“A previous study showed that exenatide improved the insulin secretion of β-cells as compared to the insulin glargine in a similar glycemic control, and this effect was sustained after a 4-week off-drug period [28].”
Kondo, Y., Satoh, S., Osada, U. N., & Terauchi, Y. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0206 · Cited by 16
Gallwitz, B., & Bretzel, R. G. (2013) · Diabetes Care · doi:10.2337/dcs13-2012 · Cited by 16
“Two head-to-head studies of GLP-1 RAs, using either exenatide once per week or liraglutide once a day, found superiority or noninferiority in terms of lowering HbA1c compared with basal insulin glargine (21,22).”
BackgroundResultKajiwara, M., Tanaka, A., Kawasaki, T., Nakao, K., Sakamoto, T., Toyoda, S., Inoue, T., Koga, N., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.009 · Cited by 13
Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
Trautmann, M., van Gaal, L., Han, J., & Hardy, E. (2017) · Journal of diabetes and its complications · doi:10.1016/j.jdiacomp.2017.06.004 · Cited by 12
Umpierrez, G. E., & Meneghini, L. (2013) · Endocrine Practice · doi:10.4158/ep12292.ra · Cited by 12
Implications of incretin-based therapies on cardiovascular disease
Rotz, M. E., Ganetsky, V. S., Sen, S., & Thomas, T. F. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12572 · Cited by 14
Incretin-based therapy and pancreatic beta cells
Chon, S., Riveline, J., Blondeau, B., & Gautier, J. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.05.003 · Cited by 13
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Kassem, L. S., Rajpal, A., Barreiro, M. V. E., & Ismail‐Beigi, F. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13446 · Cited by 16
“113 Additionally, exenatide treatment was associated with continued weight loss and improvement in whole body insulin sensitivity.”
BackgroundInfluentialLong-term studies of treatments for type 2 diabetes
Caballero, A. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1265417 · Cited by 12
Alatrach, M., Agyin, C., Solis‐Herrera, C., Lavryneko, O., Adams, J. M., Gastaldelli, A., Triplitt, C. L., DeFronzo, R. A., & Cersósimo, E. (2022) · Diabetes Care · doi:10.2337/dc21-1798 · Cited by 11
Garber, A. J. (2015) · Endocrine Practice · doi:10.4158/ep14460.ra · Cited by 12
Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Pathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_8-1 · Cited by 13
Peterson, G. M. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.653392 · Cited by 11
“In addition, although no studies to date have demonstrated long-term effects on β -cell function after cessation of treatment with exenatide or liraglutide, it has been shown that, after 52 weeks, stopping exenatide results in reversal of any improvements in β -cell function to baseline levels, including A1C and plasm…”
BackgroundMeier, J. J., Schenker, N., Kahle, M., Schliess, F., Kapitza, C., & Menge, B. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12968 · Cited by 11
“Insulin secretion rates were to be calculated by deconvolution analysis based on a two-compartment model of C-peptide elimination and calculated from IVGTT-related C-peptide concentration–time profiles using the ISEC computer program.(8) For the efficacy analysis, data from all randomized participants who received at…”
MethodShi, X., Shi, Y., Chen, N., Lin, M., Su, W., Zhang, H., Liu, C., Song, H., Xiao, F., Huang, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02631-1 · Cited by 10
Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes
Siasos, G., Bletsa, E., Stampouloglou, P. K., Paschou, S. Α., Oikonomou, E. K., Tsigkou, V., Antonopoulos, A. S., Vavuranakis, M., & Tousoulis, D. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201109110107 · Cited by 10
Hannon, T. S., Kirkman, M. S., Patel, Y. R., Considine, R. V., & Mather, K. J. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2553 · Cited by 10
Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels
Smits, M. M., Bunck, M. C. M., Diamant, M., Corner, A., Eliasson, B., Heine, R. J., Smith, U., Yki‐Järvinen, H., & van Raalte, D. H. (2015) · Diabetes Care · doi:10.2337/dc15-2489 · Cited by 9
“Details of the study design were reported previously (4).”
BackgroundSelf-citationAbdul‐Ghani, M. A., Migahid, O., Megahed, A., Singh, R., Kamal, D., DeFronzo, R. A., & Jayyousi, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13189 · Cited by 9
Abdul‐Ghani, T., PUCKETT, C. L., Migahid, O., Abdelgani, S., Migahed, A., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., Jayyousi, A., & Abdul‐Ghani, M. A. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14767 · Cited by 10
Yang, J., Xiao, W., Guo, L., Li, Q., Zhong, L., Yang, J., Yang, J., Gao, Y., Tian, Q., & Hong, T. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01510-y · Cited by 8
“results; (9) women who were pregnant, lactating or had a recent pregnancy plan.”
BackgroundMari, A., Rosenstock, J., Ma, X., Li, Y. G., & Jackson, J. A. (2015) · Endocrine Practice · doi:10.4158/ep15898.or · Cited by 9
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
Rasalam, R. R., Barlow, J., Kennedy, M., Phillips, P., & Wright, A. F. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0642-2 · Cited by 11
Federici, M. O., Gentilella, R., Corcos, A., Torre, E., & Genovese, S. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3434 · Cited by 8
ALi, A., Manzoor, U., Ali, S. L., Marsool, M. D. M., Parida, P. K., Marsool, A. D. M., & Swathi, N. L. (2023) · doi:10.53555/jptcp.v30i18.3467 · Cited by 7
Musale, V., Guilhaudis, L., Abdel‐Wahab, Y. H. A., Flatt, P. R., & Conlon, J. M. (2018) · Biochimie · doi:10.1016/j.biochi.2018.09.008 · Cited by 7
Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes
Abdelgani, S., PUCKETT, C. L., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab403 · Cited by 8
Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.
Edwards, C. (2013) · British journal of hospital medicine · doi:10.12968/hmed.2013.74.4.198 · Cited by 7
Wal, P., Aziz, N., Prajapati, H., Soni, S., & Wal, A. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998263079231011073803 · Cited by 9
Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?
Holst, J. J. (2013) · Diabetologia · doi:10.1007/s00125-013-2984-z · Cited by 6
“A similar reservation applies to the observed beta cell hyperplasia: some years ago a trophic effect on beta cells would have been received with enthusiasm, because it would support notions of protective or restitutive effects of the GLP-1 therapies on beta cells, but despite the potential to enhance beta cell mass in…”
ResultIványi, T., Fövényi, J., Faludi, P., Han, J., MacConell, L., Wille, S. A., & Kiljanski, J. I. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.022 · Cited by 6
Implantable device actuated by manual button clicks for noninvasive self‐drug administration
Kim, C. R., Cho, Y. C., Lee, S. H., Han, J. H., Kim, M. J., Ji, H. B., Kim, S., Min, C. H., Shin, B. H., Lee, C., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10320 · Cited by 5
“known to reduce hepatic insulin resistance by increasing beta-cell mass.(39) With respect to other PD parameters of exenatide, both Inj-Ex”
BackgroundPrecision and accuracy of hyperglycemic clamps in a multicenter study
Mather, K. J., Tjaden, A. H., Hoehn, A., Nadeau, K. J., Buchanan, T. A., Kahn, S. E., Arslanian, S. A., Caprio, S., Atkinson, K. M., Cree‐Green, M., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00598.2020 · Cited by 5
Chen, X., Xu, Y., Zhang, J., Shao, S., Duan, Y., Liu, P., Shen, L., Zhang, J., Zeng, J., Lin, M., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.03.015 · Cited by 6
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.15 · Cited by 7
“Thus, normalization of beta cell function has been shown within 8 hours after a single injection of liraglutide (21) and persisted for up to 3 years with exenatide (22).”
BackgroundIntervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes
Hao, S., Umpierrez, G. E., & Vellanki, P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.004 · Cited by 6
Metadata
- Authors
- Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Helsinki University Hospital (FI)
- Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Goteborg, Sweden
- Eli Lilly (United States) (US)
- Eli Lilly (Netherlands) (NL)
- Sahlgrenska University Hospital (SE)
- Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Corresponding author
- Bunck, Mathijs C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-08-19
- Volume
- 34
- Issue
- 9
- Pages
- 2041-2047
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3161303
- OpenAlex
- W2029228033
- Cited by
- 240
- References
- 25
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 10 · 2022: 11 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 20 · 2017: 29 · 2016: 24 · 2015: 23 · 2014: 27 · 2013: 28 · 2012: 12
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, insulin glargine, type 2 diabetes, metformin, beta-cell function, insulin secretion, insulin sensitivity, disposition index, glycemic control, body weight, long-term treatment, GLP-1 receptor agonists
- MeSH terms
- Insulin Glargine, Exenatide, Adult, Aged, Blood Glucose, Body Weight, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Insulin, Long-Acting, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.